Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.75 |
| ▸ | PRAP1 | Q96NZ9 | 1/20 | 0.75 |
| ▸ | TNKS | O95271 | 1/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.72 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.72 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.72 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.72 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.72 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.72 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.72 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.72 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.72 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.72 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.72 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.72 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.72 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8011744 | 0.91 | PARP1 (0.73) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL22676784 | 0.90 | PARP1 (0.69) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL30332603 | 0.89 | PARP1 (0.79) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL78306 | 0.87 | PARP1 (0.80) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL78202 | 0.87 | PARP1 (0.82) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL19569971 | 0.87 | PARP1 (0.90) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL10054133 | 0.87 | PARP1 (0.79) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL27015363 | 0.87 | PARP1 (0.80) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL25150398 | 0.87 | PARP1 (0.79) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL30364626 | 0.87 | PARP1 (0.79) | PARP1PRAP1TNKSADORA1CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885PRAP1 1833/4885TNKS 2187/4885 |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885PRAP1 1833/4885TNKS 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.